These two stocks are poised to crush the market thanks to their outsize growth prospects and dirt cheap valuations.

COVID-19 vaccines target emerging variants, offering improved protection. Learn about their effectiveness, timing, and safety ...

A new analysis of health data from Ontario, Canada, suggests that nirmatrelvir-ritonavir (Paxlovid) may provide limited benefit for vaccinated older adults with COVID-19, despite its previously proven ...

PFE offers a 6.73% dividend yield and growth potential, driven by strategic acquisitions, R&D, and discounted valuations.

Paxlovid does not significantly reduce COVID-19 hospitalization and mortality among vaccinated older adults, according to new UCLA-led research.

The antiviral pill Paxlovid does not significantly reduce COVID-19 hospitalizations in vaccinated older adults, according to ...

Adding a personalized mRNA vaccine to standard treatment could offer new hope for pancreatic cancer patients, a small yet ...

Paxlovid may not decrease the risk for hospitalization or death in older adults vaccinated against COVID-19 as much as ...

The authors compared outcomes among adults just under 70 years who were not prescribed Paxlovid to those who were given the ...

Bay Area News Group: Berkeley Man Sues Kaiser Permanente, Accuses Medical Assistant Of Sexual Assault During Cancer Surgery A Kaiser Permanente patient filed a lawsuit last week against the ...

COVID-19 treatment called into question after major study In a nutshell A major study of 1.6 million seniors found that ...

Paxlovid may offer marginal benefits for low-risk children with COVID-19; however, among high-risk children with COVID-19, Paxlovid is a safe oral option.